Truist analyst Richard Newitter raised the firm’s price target on Globus Medical (GMED) to $115 from $105 and keeps a Buy rating on the shares. The firm cites the company’s “impressive” Q4 earnings beat and expects Globus to continue growing above market in US Core Spine in 2026, which should “more than offset capital lumpiness”, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $115 from $112 at Canaccord
- Globus Medical: Sustained Outperformance, Margin Expansion, and Acquisition Synergies Support Buy Rating
- Buy Rating Reaffirmed on Strong Q4 Performance, Raised 2026 EPS Outlook, and Robust Spine & Robotics Growth Prospects
- Globus Medical price target raised to $123 from $118 at Barclays
- Globus Medical reports Q4 EPS $1.28, consensus 96c